Bevacizumab biosimilar - Oncobiologics

Drug Profile

Bevacizumab biosimilar - Oncobiologics

Alternative Names: ONS-1045

Latest Information Update: 24 Oct 2016

Price : $50

At a glance

  • Originator Oncobiologics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Colorectal cancer; Lung cancer

Highest Development Phases

  • Phase I Colorectal cancer; Lung cancer

Most Recent Events

  • 24 Oct 2016 Phase-I development is ongoing in the Netherlands
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-cancer in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top